Αρχική World News The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce

The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce

September 27, 2018, by Dinah Singer, Ph.D.

Credit: National Cancer Institute

With the increasing use of advanced technologies and the rise of big data in cancer research, a challenge for the cancer research community has been sustaining a stable workforce of experienced scientists with the skills and expertise to take fullest advantage of these tools and resources to better understand the complexities of cancer.  

In response to this challenge, NCI launched a new grant opportunity in 2016 called the R50 Research Specialist Award. In fact, the funding announcements for 2019 R50 grants were released just last month and we’re hoping to receive many applications from qualified candidates.

Although NCI and other NIH institutes offer many funding opportunities for independent investigators who operate their own labs or large research projects, NCI’s R50 grant is the only one intended to support experienced scientists who are not independent investigators.

The staff and data scientists who can apply for the R50 award are often intimately involved in essential cancer research projects that use highly sophisticated experimental approaches and an expanding suite of advanced technologies.

The roles of these research specialists can include  pursuing lab-based basic cancer biology and preclinical research, performing high-throughput assays to identify potential cancer drugs, developing software and analyzing big data from cancer studies, and managing research cores—shared research facilities for scientists that specialize in specific, often highly technical, experimental techniques (e.g., high-throughput single-cell sequencing to understand how different cancer cells in a tumor respond to a drug). The value and importance of these scientists in cancer research cannot be overstated.

The R50 award supports staff researchers, core facility managers, and data scientists with up to 5 years of salary support and annual travel funds for cancer research conferences and trainings. The recognition and funding of the R50 aims to attract and maintain important research specialists who are essential for NCI-funded research programs. Currently, over 50 research specialists receive R50 funding.

Scientists who have received R50 awards report that the financial support and stability it provides allows them to be more productive in their research, gives them time to work on developing new experimental methods, and provides travel opportunities to work with scientists at other universities. (See sidebar)

Dinah Singer, Ph.D.
Director, NCI Division of Cancer Biology

Credit: National Cancer Institute

The Importance of a Stable Workforce for Cancer Research

NCI’s mission is to conduct and support cancer research to advance the understanding, prevention, diagnosis, and treatment of cancer to help people live longer, healthier lives.  Strengthening the cancer research workforce is imperative for this research mission.

The R50 award also helps NCI overcome a major barrier in maintaining a sustainable cancer research workforce. The reliance of many laboratories on graduate students and post-doctoral fellows for research has led to problems of long-term laboratory stability. By supporting experienced staff and data scientists who improve research efficiency and play an important role in ongoing research projects, the R50 contributes to the amelioration of this research workforce issue.

The R50 award for staff and data scientists within NCI-funded programs is one way that NCI is supporting a stable workforce to advance cancer research.

I encourage staff researchers in labs, managers of core facilities, and computational scientists in data science centers to apply for a lab-based or core-based R50 award by January 11, 2019.

NCI wants to recognize the importance of the research specialist to the cancer research enterprise by enabling these exceptional scientists to have a sustainable cancer research career and continue to make progress in studies of cancer.

What Has the R50 Award Meant to You?

An R50 award can have significant and long-lasting benefits for the scientists who receive them. Here’s a sampling of what some had to say about the impact the R50 award has had on their careers:

“I don’t have to focus as much time on writing grants or worrying about my job security. I can spend more time doing research and publishing it.” Laura Pascal, Ph.D., research assistant professor, University of Pittsburgh

“The [R50 award] travel stipend enables me to host training workshops outside the Broad Institute on using our software to study cancer biology.” Brian Haas, M.S., senior computational biologist, Broad Institute

“With the salary support from the R50, I’ve been able to concentrate on the technical work at my facility and developing new methods in metabolomics for the cancer research community.” Wenyun Lu, Ph.D., the technical director of the Regional Metabolomics Core at Princeton University

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...

31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During the Pandemic

The COVID-19 pandemic has been a scary and difficult thing for most of the world, and it’s important to keep safety protocols in place...

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role

October 19, 2020, by NCI Staff An esophagram using barium contrast shows the esophagus. Credit: iStock Immunotherapy may become part of early treatment for some people with...

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...